NCT06206083Recruiting
Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis
Source: ClinicalTrials.gov · Last updated 28 Feb 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Endometrial cancer (EC) is one of the most common gynecological neoplasms, being the second in incidence and third in mortality in Mexico. Recent studies show that EC molecular classification (Cancer Genome Atlas Research Network, 2013) serves to establish a more accurate prognosis in these patients and regulate therapeutic behavior in a personalized manner. However, there are no studies on EC molecular classification in Mexican women or its impact on prognosis and the possible modification of targeted treatment. The investigators will determine the molecular classification in EC by next-generation sequencing (NGS) to detect TP53 and POLE somatic mutations, and immunohistochemical detection of microsatellite instability (MSH2, MLH1, PMS1, PMS2, MSH6, and MSH3) in a cohort of patients with endometrioid-type EC, endometrioid subtype, attended at the Instituto Nacional de Cancerología - Mexico (INCan) and determine its impact on clinical prognosis.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 64 (estimated)
- First submitted
- 5 Dec 2023
- Start date
- 1 Mar 2024
- Primary completion date
- 1 Nov 2026
- Lead sponsor
- National Institute of Cancerología
- Diseases
- Endometrial cancer
- NCT number
- NCT06206083
What you commit to
- Study type: Observational
- Planned participants: 64
- From 1 Mar 2024 to the primary completion date, 1 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Samples from patients with double primary neoplasm, including carcinoma ductal in situ, squamous cell skin cancers, and cervical carcinoma in situ
Age
- History of malignancy \< 5 years prior with no evidence of disease (i.e., remission).
Other
- Samples with CEE of non-endometroid type.
Criteria the registry did not label
- Criteria: Inclusion Criteria:
- Clinical diagnosis of endometrioid-type endometrial cancer with samples available
- That the patients have undergone surgery at INCan.
Age in the registry: 18 years to - · Sex: Female
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Instituto Nacional de Cancerologia Coordinator of this site? Confirm its status | Mexico City | Mexico | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.